Global Central Venous Catheters Market was Valued $582.2m in 2010

Tuesday 31 January 2012, Amsterdam

The report provides market landscape, competitive landscape and market trends information on the central venous catheters market. The report provides comprehensive information on the key trends affecting the market, and key analytical content on the market’s dynamics. The report also reviews the competitive landscape and technology offerings.

Global Central Venous Catheters Market was Valued $582.2m in 2010

See figure: Central Venous Catheters Market, Global, Revenue ($m), 2003-2017
 
The global central venous catheters market was valued at $582.2m in 2010, having grown at a Compound Annual Growth Rate (CAGR) of 5.1% from $411.7m in 2003. The central venous catheters market is expected to grow at a CAGR of 3.2% to $727.4m in 2017. The antimicrobial central venous catheters market segment is expected to show the highest growth at a CAGR of 4.5% from 2010 to 2017.

The antimicrobial central venous catheters market segment is expected to grow due to the increased focus on prevention of Healthcare Associated Infection (HAI), while the non-antimicrobial central venous catheters market segment will grow due to its low cost.
 

The US was the Largest Central Venous Catheters Market in 2010 worth $295m

The largest central venous catheters market was that of the US, which was valued at $295m in 2010, having grown at a CAGR of 4.5% from 2003. The non-antimicrobial central venous catheters market segment was the largest market segment with revenues of $193.9m in 2010. The antimicrobial central venous catheters market segment was valued at $101.1m in 2010.

Patients who require the external administration of nutrition and medication consequently require the use of central venous catheters. The American Cancer Society estimates that about 1.64 million new cases of cancer will be detected in the US in 2012. The National Institutes of Health (NIH) estimate that the total costs due to cancer in 2007 were $226.8 billion, comprising $103.8 billion in direct medical costs and $123 billion in indirect mortality costs. Significant attention towards prevention of HAIs by the healthcare payers is also expected to drive the market growth.

Teleflex Incorporated Leads the Global Central Venous Catheters Market

Teleflex Inc. was the market leader in the central venous catheters market in 2010 with a share of 47%. Teleflex acquired VasoNova in January 2011 and gained access to VasoNova’s central venous catheters product portfolio and their real-time catheter tip positioning method. The ARROWg+ard technology enables the company to maintain a leading position in the market.
C. R. Bard and B. Braun also have significant presence in the global central venous catheters market.

Increase in the Number of Patients Requiring Parenteral Nutrition to Increase the Usage of Central Venous Catheters

Patients suffering from diseases such as cancer are often unable to receive fluids or medication via the traditional route, meaning that they must be administered externally. This is done using a central venous catheter, which is placed on the central line.

The International Agency for Research on Cancer (IARC) estimates that the total number of new cancer cases globally will rise to 21.4 million by 2030 and that the total number of deaths from cancer will reach 13.2 million. The growth and aging of the population are the main factors contributing to the rise in the number of cancer cases.

This increases the dependence on parenteral nutrition in cancer patients. Conditions such as Acquired Immune Deficiency Syndrome (AIDS) and Gastrointestinal (GI) infections also make it difficult for patients to receive medication or food, leading to growth in the central venous catheters market.